Appraising the Effects of Metabolic Traits on the Risk of Glaucoma: A Mendelian Randomization Study
Metabolites · 09.01.2023 · 13 (1) · 109
DOI: 10.3390/metabo13010109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolites, online erschienen am 09.01.2023. Verfasst von Kai Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Public Welfare Technology Research Project, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Metabolic traits are associated with the risk of developing glaucoma in observational studies. To assess whether theses associations reflect causality, we conducted a Mendelian randomization (MR) study. Our study included up to 20,906 glaucoma cases and 438,188 controls. Genetic instruments associated with the concerned 11 exposures at the genome-wide significance level were selected from corresponding genome-wide association studies. Summary-level data for glaucoma were obtained from the UK Biobank, the GERA study, and the FinnGen consortium. Univariable and multivariable MR analyses were conducted separately in two populations. Our results showed that higher genetic liability to type 2 diabetes (T2D) was causally and independently associated with an increased risk of glaucoma (odds ratio [OR], 1.11; 95% confidence interval [CI], 1.06–1.16; p = 4.4 × 10−6). The association for T2D persisted after multivariable adjustment. In addition, higher genetically predicted systolic blood pressure (SBP), fasting glucose (FG), and HbA1c, were also suggestively associated with glaucoma risk. The OR was 1.08 (95% CI, 1.01–1.16; p = 0.035) for SBP, 1.24 (95% CI, 1.05–1.47; p = 0.011) for FG, and 1.28 (95% CI, 1.01–1.61; p = 0.039) for HbA1c. No evidence was observed to support the causal effects of body mass index and blood lipids for glaucoma. This study suggests a causal role for diabetes, as well as possible roles for higher SBP, FG, and HbA1c in the development of glaucoma. Further validation is needed to assess the potential of these risk factors as pharmacological targets for glaucoma prevention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
- Department of Cardiology, Ningbo First Hospital, Ningbo 315010, China.
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou 311121, China.
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Public Welfare Technology Research Project
- China Postdoctoral Science Foundation
- Key Research and Development Project of Zhejiang Province
- the Organ Reconstruction and Manufacturing, Strategic Priority Research Program of the Chinese Academy of Sciences
- Zhejiang Provincial Natural Science Foundation of China
- Medical Research Council
- National Natural Science Foundation
Zitieren
APA
Wang, K., Yang, F., Liu, X., Lin, X., Yin, H., Tang, Q., Jiang, L., & Yao, K. (2023). Appraising the Effects of Metabolic Traits on the Risk of Glaucoma: A Mendelian Randomization Study. Metabolites, 13(1), 109. https://doi.org/10.3390/metabo13010109
Vancouver
Wang K, Yang F, Liu X, Lin X, Yin H, Tang Q, et al. Appraising the Effects of Metabolic Traits on the Risk of Glaucoma: A Mendelian Randomization Study. Metabolites. 2023;13(1):109. doi:10.3390/metabo13010109
BibTeX
@article{Wang2023,
author = {Wang, Kai and Yang, Fangkun and Liu, Xin and Lin, Xueqi and Yin, Houfa and Tang, Qiaomei and Jiang, Li and Yao, Ke},
title = {Appraising the Effects of Metabolic Traits on the Risk of Glaucoma: A Mendelian Randomization Study},
journal = {Metabolites},
year = {2023},
volume = {13},
number = {1},
pages = {109},
doi = {10.3390/metabo13010109}
}
EUVIMED